ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Acquired by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC boosted its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 43.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 65,179 shares of the biopharmaceutical company’s stock after acquiring an additional 19,871 shares during the period. Los Angeles Capital Management LLC’s holdings in ACADIA Pharmaceuticals were worth $2,041,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in ACAD. RTW Investments LP lifted its position in shares of ACADIA Pharmaceuticals by 18.3% in the 3rd quarter. RTW Investments LP now owns 11,576,537 shares of the biopharmaceutical company’s stock worth $241,255,000 after buying an additional 1,793,288 shares during the last quarter. Fred Alger Management LLC boosted its stake in ACADIA Pharmaceuticals by 38.7% in the third quarter. Fred Alger Management LLC now owns 3,108,883 shares of the biopharmaceutical company’s stock valued at $64,789,000 after acquiring an additional 867,818 shares during the period. Sectoral Asset Management Inc. bought a new position in shares of ACADIA Pharmaceuticals during the third quarter valued at approximately $4,376,000. Qube Research & Technologies Ltd raised its position in shares of ACADIA Pharmaceuticals by 757.2% during the 3rd quarter. Qube Research & Technologies Ltd now owns 212,919 shares of the biopharmaceutical company’s stock worth $4,437,000 after purchasing an additional 188,080 shares during the period. Finally, Fisher Asset Management LLC acquired a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $4,479,000. Institutional investors own 96.71% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on ACAD. JMP Securities reiterated a “market outperform” rating and issued a $42.00 target price on shares of ACADIA Pharmaceuticals in a research note on Wednesday, February 7th. JPMorgan Chase & Co. cut their price objective on shares of ACADIA Pharmaceuticals from $29.00 to $25.00 and set an “overweight” rating on the stock in a research note on Monday, March 25th. Royal Bank of Canada decreased their target price on shares of ACADIA Pharmaceuticals from $36.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. Oppenheimer restated a “market perform” rating and set a $19.00 price target on shares of ACADIA Pharmaceuticals in a research report on Monday. Finally, Mizuho lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $39.00 to $25.00 in a research note on Tuesday, March 12th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $31.75.

Insider Activity at ACADIA Pharmaceuticals

In other news, CFO Mark C. Schneyer sold 3,503 shares of the company’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $16.94, for a total value of $59,340.82. Following the transaction, the chief financial officer now owns 32,053 shares in the company, valued at approximately $542,977.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Stephen Davis sold 5,577 shares of ACADIA Pharmaceuticals stock in a transaction on Monday, February 26th. The stock was sold at an average price of $24.67, for a total transaction of $137,584.59. Following the completion of the sale, the chief executive officer now owns 101,890 shares of the company’s stock, valued at $2,513,626.30. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Mark C. Schneyer sold 3,503 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $16.94, for a total value of $59,340.82. Following the completion of the transaction, the chief financial officer now owns 32,053 shares in the company, valued at approximately $542,977.82. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 89,116 shares of company stock valued at $1,625,639. Company insiders own 27.50% of the company’s stock.

ACADIA Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ ACAD opened at $17.00 on Tuesday. The business has a fifty day simple moving average of $18.97 and a 200-day simple moving average of $23.29. The company has a market cap of $2.81 billion, a price-to-earnings ratio of -44.74 and a beta of 0.42. ACADIA Pharmaceuticals Inc. has a 12 month low of $16.16 and a 12 month high of $33.99.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.04). ACADIA Pharmaceuticals had a negative return on equity of 15.67% and a negative net margin of 8.44%. The firm had revenue of $231.04 million during the quarter, compared to analyst estimates of $223.79 million. During the same period in the prior year, the business posted ($0.26) EPS. The company’s revenue for the quarter was up 69.3% on a year-over-year basis. As a group, sell-side analysts expect that ACADIA Pharmaceuticals Inc. will post 0.62 EPS for the current fiscal year.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.